NMRA Live signaler | Maksimer profitt med Getagraph.com

KJøP 121167 min ago

@ $18.19

Utstedt: 14 feb 2024 @ 18:07

Avkastning: -48.21%

Forrige signal: feb 14 - 17:05

Forrige signal: Selg

Avkastning: -1.41 %

Live Chart Being Loaded With Signals

Commentary (8 mai 2024 @ 22:00):

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases...

Stats
Dagens volum	412 520
Gjennomsnittsvolum	607 950
Markedsverdi	1.50B
EPS	$0 ( 2024-03-13 )
Neste inntjeningsdato	( $-0.350 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.60
ATR14	$0.0160 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Arch Venture Partners Xii, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners Xii, Llc	Buy	703 061	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	703 061	Common Stock
2023-12-08	Burow Kristina	Buy	1 176 593	Common Stock

INSIDER POWER
35.65
Last 85 transactions
Buy: 48 806 253 \| Sell: 23 661 663

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: -0.43 (neutral)

Signal:(70.152) Neutral

Neumora Therapeutics, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Neumora Therapeutics, Korrelasjon - Valuta/Råvare

0.15
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.38
( neutral )

-0.77
( moderate negative )

-0.08
( neutral )

Neumora Therapeutics, Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.860

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Neumora Therapeutics,

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.